Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CALML3 | P27482 | 1/20 | 0.37 |
| ▸ | SDHA | P31040 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449728 | 0.89 | RAB9A (0.37) | F10ALDH1A1LMNAMAOAPTGS1 | |
| SCHEMBL3450659 | 0.87 | F10 (0.48) | F10 | |
| SCHEMBL3449732 | 0.80 | F10 (0.54) | F10 | |
| SCHEMBL3447220 | 0.80 | F10 (0.49) | F10MTORALDH1A1RAB9A | |
| SCHEMBL3448390 | 0.78 | F10 (0.42) | F10 | |
| SCHEMBL4592257 | 0.77 | F10 (0.46) | F10MTOR | |
| SCHEMBL3448148 | 0.73 | F10 (0.48) | F10 | |
| SCHEMBL3451523 | 0.73 | F10 (0.54) | F10 | |
| SCHEMBL3454411 | 0.71 | F10 (0.48) | F10 | |
| SCHEMBL3448763 | 0.70 | F10 (0.54) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | claimed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247238-A1 | Cyclic amines | F12, F11, F2 | F10 4/4885MTOR 2993/4885ALDH1A1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.